Appropriate selection of candidates for PSMA RLT requires, among others, imaging with PSMA-directed positron emission tomography/computed tomography (PET/CT), using gallium-68 or fluorine-18-labeled radioligands in order to confirm overexpression of PSMA on tumor lesions—a pre-requisite for therapy [10]. Here, FOLH1 is linked to neoplasm.